Institut Pasteur undertakes longitudinal follow-up of a population cohort in a French city with high SARS-CoV-2 circulation
Photo by Luiza Giannelli
Institut Pasteur is conducting the clinical trial Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation in Early 2020 (COVID-OISE).
An initial epidemiological investigation was conducted in a city north of France after the diagnosis of the first case of COVID-19 on February 2020. Other studies were conducted in this town by the Institut Pasteur in early 2020 among families, teachers and non-teaching staff of the high and elementary schools.
The goal of this new project is to better characterize the specific immunity generated by the infection within this community. The specific immune response to the SARS-CoV-2 virus will be followed for a period of 2 years from the initial circulation of the virus, within a large cohort of participants covering all age groups from 5 years-old onwards. The study will focus on systemic humoral and T-cell responses, immunity of the nasopharyngeal mucosa and the humoral response present in saliva. Follow-up of participants in this cohort and monitoring of the virus circulation within this community would help to determine the protective character against re-infection of the natural immunity generated by SARS-CoV-2.
This study will focus on systemic humoral and T-cell responses, immunity of the nasopharyngeal mucosa and the humoral response present in saliva. The genetic basis of the diversity of humoral responses induced by SARS-CoV-2 and those related to the multiplicity of clinical manifestations of COVID-19 will also be investigated. This would provide initial evidence to determine the protective character against re-infection of the natural immunity generated by CoV-2-SARS. Finally, these data will be used to model the intra-family transmission of the virus.
It is planned to include 2000 participants.
Actual study start date is November 13, 2020. The researchers expect to complete the study by November 1, 2023.
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups is primary outcome measure.
The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT04644159) Crepy-en-Valois, Paris, France.
